<DOC>
	<DOCNO>NCT01685125</DOCNO>
	<brief_summary>This phase II trial study well give abiraterone acetate prednisone without dasatinib work treat patient metastatic , hormone-resistant prostate cancer . Androgens cause growth prostate cancer cell . Antihormone therapy , abiraterone acetate , may lessen amount androgen make body . Dasatinib may stop growth tumor cell block enzymes need cell growth . It yet know whether abiraterone acetate prednisone effective abiraterone acetate , prednisone , dasatinib treat prostate cancer</brief_summary>
	<brief_title>Abiraterone Acetate Prednisone With Without Dasatinib Treating Patients With Metastatic Hormone-Resistant Prostate Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To compare progression-free survival men metastatic castration-resistant prostate cancer treat abiraterone ( abiraterone acetate ) plus dasatinib men treat abiraterone alone . SECONDARY OBJECTIVES : I . To describe toxicity profile combination , well rate prostate-specific antigen ( PSA ) response , objective response , change circulate tumor cell ( CTC ) number . OUTLINE : Patients randomize 1 2 treatment arm . ARM A : Patients receive abiraterone acetate 1000 mg orally ( PO ) daily ( QD ) prednisone 5 mg PO twice daily ( BID ) day 1-28 . Courses repeat every 4 week absence disease progression unacceptable toxicity . ARM B : Patients receive abiraterone acetate prednisone patient arm A . Patients also receive dasatinib 100 mg PO QD day 1-28 . Courses repeat every 4 week absence disease progression unacceptable toxicity . After completion study treatment , patient follow periodically .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Abiraterone Acetate</mesh_term>
	<mesh_term>Dasatinib</mesh_term>
	<criteria>Metastatic , castrationresistant prostate cancer Defined evaluable radiographic disease rise PSA x 2 ( least 1 week apart ) radiographic progression ( new soft tissue/bone lesion enlarge soft tissue lesion ) despite medical surgical castration No limit prior hormonal therapy ( i.e . antiandrogens , ketoconazole ) except subject must receive abiraterone previously No limit prior biologic therapy ( i.e . immune therapy , antiangiogenic , target ) except patient receive dasatinib vsrc sarcoma ( SchmidtRuppin A2 ) viral oncogene homolog ( avian ) ( src ) target therapy No prior chemotherapy metastatic disease * Subjects receive chemotherapy neoadjuvant adjuvant set eligible provide chemotherapy complete &gt; 6 month prior enrollment Eastern Cooperative Oncology Group ( ECOG ) 02 Total bilirubin = &lt; 1.5 time institutional upper limit normal ( ULN ) except Gilbert 's syndrome Hepatic enzyme ( aspartate aminotransferase [ AST ] , alanine aminotransferase [ ALT ] ) = &lt; 2.5 time institutional ULN Serum sodium ( Na ) , potassium ( K+ ) , magnesium ( Mg+ ) , phosphate calcium ( Ca+ ) &gt; low limit normal ( LLN ) Serum creatinine = &lt; 1.5 time institutional ULN Hemoglobin ( Hb ) &gt; = 9 Platelets &gt; = 100,000 Absolute neutrophil count ( ANC ) &gt; = 1000 Ability take oral medication ( study medication must swallow whole ) Men father potential must agree use contraception throughout study treatment ; acceptable method include : condom , sponge , intrauterine device ( IUD ) , oral contraceptive Concomitant medication * Patient agree discontinue St. Johns wort receive dasatinib therapy ( discontinue St. Johns wort least 5 day start dasatinib ) Known hepatitis B C human immunodeficiency virus ( HIV ) , regardless viral load * Testing purpose enrollment mandatory , however documented history infection exclusionary due concern drugdrug interaction antiviral potential increase risk liver toxicity Radiation palliation bony metastasis within precede 2 week Prior chemotherapy metastatic castrationresistant prostate cancer ( CRPC ) * Immune therapy sipuleucelT allow , provide last infusion &gt; = 28 day prior study therapy least one document PSA value rise completion sipuleucelT therapy progression disease image sipuleucelT Malignancy ( aside prostate cancer ) require radiotherapy systemic treatment within past 5 year Superficial bladder cancer treat intravesical therapy currently remission exclusion Skin cancer exclusion , except melanoma thickness &gt; 1 mm Concurrent medical condition may increase risk toxicity , include : Pleural pericardial effusion grade time study entry Cardiac symptom ; follow consider exclusion : ** Uncontrolled angina , congestive heart failure myocardial infarction ( MI ) within ( 6 month ) Diagnosed congenital long QT syndrome Any history clinically significant ventricular arrhythmia ( ventricular tachycardia , ventricular fibrillation , Torsades de pointes ) ** Prolonged QTc/f interval preentry electrocardiogram ( &gt; 450 msec ) Hypokalemia hypomagnesemia correct prior abiraterone administration History significant bleeding disorder unrelated cancer , include : Diagnosed congenital bleeding disorder ( e.g. , von Willebrand 's disease ) Diagnosed acquire bleed disorder within one year ( e.g. , acquire antifactor VIII antibody ) Ongoing recent ( = &lt; 3 month ) significant gastrointestinal bleeding Prohibited treatment and/or therapy Should additional anticancer therapy except luteinizing hormonereleasing hormone ( LHRH ) agonist/antagonist ; specifically exclude medication include ketoconazole , estrogen , antiandrogens Category I drug generally accept risk cause Torsades de point include : ( Patients must discontinue drug 7 day prior start dasatinib ) Quinidine , procainamide , disopyramide Amiodarone , sotalol , ibutilide , dofetilide Erythromycin , clarithromycin Chlorpromazine , haloperidol , mesoridazine , thioridazine , pimozide Cisapride , bepridil , droperidol , methadone , arsenic , chloroquine , domperidone , halofantrine , levomethadyl , pentamidine , sparfloxacin , lidoflazine Prisoners subject involuntarily incarcerate Subjects compulsorily detain treatment either psychiatric physical ( eg , infectious disease ) illness</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>